Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
Yep, apologies I meant won’t sign off without a going concern which always leads to a large fall. They’d want money sorted before prelims and of course positive data at AACR without a strong balance sheet will mean a rise quickly sold into and then likely a fall due to distressed raise (even more so!). At least now even with the shocking raise there should be a base and decent data with positive commentary rather than fluff should mean a decent rise and a licensing deal H1 will mean a very decent rise. I’m sure AS desperate for that before the AGM
Can be paid in cash and should be if the strike price is below 50p. I hope a positive AACR will have this move a fair whack higher so payment in shares I suspect
wynd - given avct had £16m in the bank there was no immediate pressing need to do the raise last month,
the above is not true. they had £16m end of jan so come end of april it will be a little over £10m and the auditor will not sign off the accounts as you need 12 months cash. i assume they had a deal that fell through so got completely shafted on the raise and ended up being forced to take 50p which is poor on the bod but they had to do so and although as a lth i am ****ed i am happy they now have over £40m in cash so 2 years and i suspect fortnightly will produce some amazing results and large cos more likely to move then so autumn or so. in the meantime aarc should be an eye opener and i am sure there wilk be several patients from cohort 3 to 6 with 6 months plus of treatment which is an improvement on the usual 6 cycles of dox over 4.5 months. also with cash they are in a better negotiatoing position as agreeing to a poor license deal sets a low bar.
Https://avacta.com/investors/corporate-governance/#evaluation_performance
Directors are subject to re-election at the Annual General Meeting following their appointment. In addition, at each Annual General Meeting one third (or whole number more than one third) of the Directors will retire by rotation.
How do you know CC has the commercial acumen? She's surely a very well suited in her current position which is crucial. If AS doesn't pull something remarkable out of the bag and has to go they'll need a more commercially savvy operator who has experience of growing PLCs from £100m market cap to £bns. Managing a smaller PLC and getting more modest raises away very different to where we are and even more so will be in 12 months or so. Anyway, here's hoping we have amazing data quickly followed by a deal to strengthen the balance sheet and validate the platform and the share price will respond and sentiment change. An interesting month or so ahead for definite.
They didn’t really move the therapeutics site to London from Cambridge. Another lie. I don’t just wanna see the Avacta labs but I want access to the independent clinicians at the hospitals where the trials are running.
Yep they’re not really doing any lab work. The patients in the trial are all bogus as is the data, biopsies and the lead investigators are going along with it as are the regulators.
More cycles and a larger TAM due to less toxicity means more revenue potential
Also, if the person with the 65% tumour reduction (3rd cohort) has been able to continue treatment he will have had AVA6000 for 15 months (most with normal dox 6 cycles or 4.5 months) and without the awful side effects. There were also several patients receiving drug beyond the usual 4.5 months so I am sure more superb stories of patients lives being extended and with much better quality of life. Hopefully 2 weekly dosing will smash it out of the park given first line treatment where possible too.
Oxygen you have a point re IIs voting in favour of the BOD but this is still massively retail based so unless something impressive comes out of the wash beforehand I suspect the CEO and CFO under a lot of pressure and there will be many votes against their reappointment. I hope CFO goes but Smith manages to pull something superb out of the bag which saves him and starts to rebuild momentum and trust
I don't think they can talk about the raise until 40 days have passed so around AACR. I agree though, TG has to go and unless AS pulls something remarkable out of the bag he has to go too. I know the chairman speaks well and great experience but he hasn't been doing his job, maybe becoming a CEO last year meant he took his eye off the ball. He needs to protect shareholders not the execs. Also CLN recalculation period in First half of April so surely AS has something to give or he surely knows he is likely toast.
BV then why say this is the RNS which implies the safety committee will need to sign off before next cohort?
Avacta anticipates that the SMDC will review the two-weekly cohort 1 data by the end of April.
Too you say 6 out of 40 patients which is true but biopsies were not expected and a bonus and the superb levels of dox measured were found in 6 out of 6 so 100% and now given what they are saying it’s now 10 out of 10. They will of course look at the PK, leaving group with all the patients so will likely have a good idea how much is getting into the tumour for all of them. Anyway, not long for the read out. Here’s hoping we have several end of life patients who have been on drug for nearly 12 months so extended their lives and without the horrendous side effects.
Thanks EA. Looks positive
How do you know he’s presenting with Avacta at AACR?
Yep so in 3 weekly it was - patient 1 dosed; 3 weeks later second dose and 2 patients get first; 3 weeks later 2 patients get second and then 2 weeks observation.
2weekly due to safety we are able to have all 3 patients dosed and 2 weeks later second dose followed by 2 weeks observation.
Exactly PL, like when the US sites came online in 3 weekly they started from cohort 5.
I think letting us know when the 3rd patient has been dosed gives us a better idea on likely completion.
BV - 35
@PL, point taken about the length of C1, but what does "in parallel" mean? Sites or cohorts? That is ambiguous and needs clarification.
The above means they can dose 3 patients at the same time rather than 1 and then wait on this case 2 weeks and then an other 2 before 2 weeks obvs ahead of sign off for next cohort. If they have patients lined up a cohort could take 4 weeks